Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (flag-IDA) for the treatment of children with poor-prognosis acute leukemia: the hacettepe experience

Pediatric Hematology and Oncology

Volumn 27, Issue 7, 2010, Pages 517-528

  Tavil, Betul ^a   Aytac, Selin ^a   Isik Balci, Yasemin ^a   Unal, Sule ^a   Kuskonmaz, Baris ^a   Yetgin, Sevgi ^a   Gurgey, Aytemiz ^a   Tuncer, Murat ^a   Gumruk, Fatma ^a   Uckan, Duygu ^a   Cetin, Mualla ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

acute leukemia; children; FLAG IDA regimen; poor prognosis

Indexed keywords

ALLOPURINOL; CORTICOSTEROID; COTRIMOXAZOLE; CYTARABINE; FLUCONAZOLE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ONDANSETRON;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; ECHOCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; ESCHERICHIA COLI INFECTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; LUNG INFECTION; LUNG MYCOSIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; PSEUDOMONAS INFECTION; SCHOOL CHILD; SEPTICEMIA; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE;

EID: 77957240852     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2010.493578     Document Type: Article

References (17)

1. Fleischhack G, Graf N, Hasan C, et al. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)-an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study]. Klin Padiatr. 1996;208:229-235.
2. Fleischhack G, Hasan C, Graf N, et al. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998;102:647-655. (Pubitemid 28387045)
3. YalmanN, SarperN,DevecioǵluO, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr. 2000;42:198-204.
4. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116-124. (Pubitemid 23059984)
5. Huhmann IM, Watzke HH, Geissler K, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73:265-271. (Pubitemid 27032720)
6. Ferrara F, Palmieri S, Pocali B, et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol. 2002;68:203-209. (Pubitemid 34717820)
7. National Cancer Institute. Common Toxicity Criteria. Available at: http://www.ucdmc.ucdavis.edu/ clinicaltrials/documents/NCI toxicity table.pdf. Accessed 27 July 2010.
8. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993;7:81-107. (Pubitemid 23052975)
9. Stahnke K, Ritter J, Schellong G, et al. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study]. Klin Padiatr. 1992;204:253-257.
10. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acutemyelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671-678. (Pubitemid 24110903)
11. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia. 1994;8:1842-1846. (Pubitemid 24363058)
12. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol. 2001;112:127-137. (Pubitemid 32151160)
13. Dinndorf PA, Avramis VI, Wiersma S, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:2780-2785. (Pubitemid 27330003)
14. Leahey A, Kelly K, Rorke LB, et al. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML). J Pediatr Hematol Oncol. 1997;19:304-308. (Pubitemid 27464887)
15. McCarthy AJ, Pitcher LA, Hann IM, et al. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol. 1999;32:411-415.
16. Anderlini P, Luna M, Kantarjian HM, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996;10:600-608. (Pubitemid 26144437)
17. Goodman ER, Fiedor PS, Fein S, et al. Fludarabine phosphate: a DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am Surg. 1996;62:435-442. (Pubitemid 26158143)